The notice states that the sale or stock or exhibit or offer for sale or distribution of any drug requires a licence from the concerned state licensing authority and conditions of a licence are required to be complied with by the licence holders.
Zydus said it is the only Indian company to have developed a neutralizing monoclonal antibody based cocktail for the treatment of COVID-19.
Covaxin is currently being administered to the people in the country along with Covishield. Hyderabad-based Bharat Biotech is manufacturing Covaxin.
Sputnik V Vaccine Approved in India: DGCI has approved Russia's Sputnik V vaccine for emergency use in India. Sputnik V becomes the third vaccine that will be administered to Indians.
Drug firm Zydus Cadila on Monday said it has sought approval from the domestic drug regulator Drugs Controller General of India (DCGI) for the additional indication of its hepatitis drug Pegylated Interferon Alpha-2b for treating COVID-19.
The expert panel of India's drug regulator, DCGI, has permitted Bharat Biotech to give the third dose of Covaxin to a few volunteers in its clinical trials of the COVID-19 vaccine.
BJP National Spokesperson Sambit Patra on monday held a press conference at BJP HQ where he hit back at the Congress over the questions raised by congress party over the DGCI's approval of two indegenous vaccines for usage.
Drug firm Zydus Cadila on Sunday said it has received DCGI approval to initiate Phase III clinical trials of its COVID-19 vaccine ZyCoV-D.
In a significant development, Drugs Controller General of India (DGCI) on Sunday (January 3) formally approved Oxford-AstraZeneca's Covishield and Bharat Biotech's Covaxin for use in India.
The expert panel has recommended granting permission for restricted emergency use of 'Covaxin' in "public interest as an abundant precaution, in clinical trial mode, especially in the context of infection by mutant strains.
Drug Controller General of India (DCGI) on Sunday approved Serum Institute of India's 'Covishield' vaccine and Bharat Biotech's 'Covaxin' for emergency use against coronavirus.
In a significant development, Drugs Controller General of India (DGCI) on Sunday (January 3) formally approved Oxford-AstraZeneca's Covishield and Bharat Biotech's Covaxin for use in India.
The AIDAN has said it is shocked to learn about the recommendation to grant REU approval to Bharat Biotech's COVAXIN in "clinical trial mode" and "specially in the context of infection by mutant strains".
The Directorate General of Goods and Services Tax Intelligence (DGGI) has found alleged evasion of GST collectively worth over Rs 108 crore by two liquor manufacturers in Aurangabad and Nanded districts of Maharashtra
The Drug Controller General of India (DCGI) issued notices to Glenmark seeking clarification from the company regarding the false claim that its antiviral drug Fabiflu, is effective on COVID-19 patients with co-morbidities.
New Delhi,Jan 13: Preparing to deal with any future chemical, biological, radiological and nuclear (CBRN) incidents, Indian scientists have devised 16 drugs that can be used for disaster management. These include an anti-cyanide drug, an
Top News
Latest News
